Clinical Trials Directory

Trials / Unknown

UnknownNCT05786378

Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
23 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
5 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Assessment of the efficacy of Intratympanic platelet rich plasma injection for treatment of idiopathic suden sensorineural hearing loss

Detailed description

Sensorineural hearing loss is the collective term for hearing damage to the cochlea and auditory nerve and is by far the most common type of hearing loss in adults, accounting for over 90% of all cases. Sensorineural hearing loss is a heterogeneous disorder, which can arise due to damage to pathway for sound impulses from the hair cells of inner ear to auditory nerve and less commonly brain. Sensorineural hearing loss is a challenge to physicians, as it progresses with age and causes significant reductions in quality of life and there are no treatments to reverse its effects, other than sound amplification with the use of hearing aids or direct auditory nerve stimulation via cochlear implantation. Platelet-rich Plasma (PRP) Therapy is a cutting-edge procedure that is revolutionizing the hearing loss and deafness. Intratympanic instillation of Platelet-rich Plasma (PRP) does wonder to the hair cells of inner ear, thus improving the hearing.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPlatelet Rich PlasmaSample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use. Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant). Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate. The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed. PRP activation prior to injection. PRP can be activated exogenously by calcium chloride.
DRUGlocal anesthesia in external auditory canallocal anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
PROCEDUREIntratympanic Injection0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.

Timeline

Start date
2023-06-01
Primary completion
2024-01-01
Completion
2024-02-01
First posted
2023-03-27
Last updated
2023-04-19

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05786378. Inclusion in this directory is not an endorsement.